Equities

Chiome Bioscience Inc

4583:TYO

Chiome Bioscience Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)150.00
  • Today's Change50.00 / 50.00%
  • Shares traded1.47m
  • 1 Year change+11.11%
  • Beta1.0421
Data delayed at least 20 minutes, as of Nov 21 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Chiome Bioscience Inc grew revenues 8.19% from 630.82m to 682.46m while net income improved from a loss of 1.24bn to a smaller loss of 1.22bn.
Gross margin53.55%
Net profit margin-209.45%
Operating margin-209.70%
Return on assets-70.61%
Return on equity-100.30%
Return on investment-95.97%
More ▼

Cash flow in JPYView more

In 2023, cash reserves at Chiome Bioscience Inc fell by 401.72m. Cash Flow from Financing totalled 667.30m or 97.78% of revenues. In addition the company used 1.07bn for operations while cash from investing totalled 173.00k.
Cash flow per share-15.67
Price/Cash flow per share--
Book value per share19.85
Tangible book value per share19.85
More ▼

Balance sheet in JPYView more

Chiome Bioscience Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio3.68
Quick ratio3.57
Total debt/total equity0.2492
Total debt/total capital0.1995
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.